BioCentury
ARTICLE | Clinical News

Immunomedics falls on Phase III miss in lupus

July 29, 2015 1:44 AM UTC

Immunomedics Inc. (NASDAQ:IMMU) sank $1.16 (31%) to $2.55 after partner UCB Group (Euronext:UCB) said epratuzumab missed its primary endpoints in the identical Phase III EMBODY 1 and EMBODY 2 trials to treat systemic lupus erythematosus (SLE).

UCB said there was no statistically significant difference between patients treated with epratuzumab plus standard therapy vs. placebo plus standard therapy. The primary endpoint was percentage of patients meeting treatment response criteria at week 48 as measured by the BILAG-based combined lupus assessment (BICLA). UCB spokesperson Andrea Christopher declined to comment on next steps for the program. ...